What is a stock summary page? Click here for an overview.
Business Description
Janux Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US47103J1051
Share Class Description:
JANX: Ordinary SharesDescription
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 44.52 | |||||
| Equity-to-Asset | 0.96 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.24 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 28.68 | |||||
| Beneish M-Score | -1.64 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 8.3 | |||||
| 3-Year EBITDA Growth Rate | -8.9 | |||||
| 3-Year EPS without NRI Growth Rate | 2.7 | |||||
| 3-Year FCF Growth Rate | -1.6 | |||||
| 3-Year Book Growth Rate | 24.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -35.46 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 48.39 | |||||
| 9-Day RSI | 44.67 | |||||
| 14-Day RSI | 41.17 | |||||
| 3-1 Month Momentum % | -41.77 | |||||
| 6-1 Month Momentum % | -31.74 | |||||
| 12-1 Month Momentum % | -15.16 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 59.21 | |||||
| Quick Ratio | 59.21 | |||||
| Cash Ratio | 58.72 | |||||
| Days Sales Outstanding | 138.22 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -12.7 | |||||
| Shareholder Yield % | -38.48 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -933.58 | |||||
| Net Margin % | -651.62 | |||||
| FCF Margin % | -417.2 | |||||
| ROE % | -10.34 | |||||
| ROA % | -9.81 | |||||
| ROIC % | -278.36 | |||||
| 3-Year ROIIC % | -278.97 | |||||
| ROC (Joel Greenblatt) % | -376.65 | |||||
| ROCE % | -14.34 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 156.49 | |||||
| PB Ratio | 1.78 | |||||
| Price-to-Tangible-Book | 1.78 | |||||
| EV-to-EBIT | -8.84 | |||||
| EV-to-Forward-EBIT | -6.68 | |||||
| EV-to-EBITDA | -9.03 | |||||
| EV-to-Forward-EBITDA | -6.76 | |||||
| EV-to-Revenue | 82.53 | |||||
| EV-to-Forward-Revenue | 174.77 | |||||
| EV-to-FCF | -19.78 | |||||
| Price-to-GF-Value | 1.8 | |||||
| Price-to-Net-Current-Asset-Value | 1.83 | |||||
| Price-to-Net-Cash | 1.85 | |||||
| Earnings Yield (Greenblatt) % | -11.31 | |||||
| FCF Yield % | -2.42 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:JANX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Janux Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 10.588 | ||
| EPS (TTM) ($) | -1.28 | ||
| Beta | 3.14 | ||
| 3-Year Sharpe Ratio | 0.53 | ||
| 3-Year Sortino Ratio | 2.76 | ||
| Volatility % | 79.57 | ||
| 14-Day RSI | 41.17 | ||
| 14-Day ATR ($) | 1.861868 | ||
| 20-Day SMA ($) | 31.0905 | ||
| 12-1 Month Momentum % | -15.16 | ||
| 52-Week Range ($) | 28.92 - 71.71 | ||
| Shares Outstanding (Mil) | 59.11 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Janux Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Janux Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Janux Therapeutics Inc Frequently Asked Questions
What is Janux Therapeutics Inc(JANX)'s stock price today?
The current price of JANX is $30.83. The 52 week high of JANX is $71.71 and 52 week low is $28.92.
When is next earnings date of Janux Therapeutics Inc(JANX)?
The next earnings date of Janux Therapeutics Inc(JANX) is 2025-05-08 Est..
Does Janux Therapeutics Inc(JANX) pay dividends? If so, how much?
Janux Therapeutics Inc(JANX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers